Status:
COMPLETED
Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute
Conditions:
Renal Impairment in Hepatorenal Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study aimed to investigate the efficacy of midodrine plus octreotide versus norepinephrine and to determine the predictive factors of response in patients with HRS-AKI.
Detailed Description
Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI based on the 2015 International Club of Ascites (ICA) diagnostic criteria \[2\] were eligible for participation....
Eligibility Criteria
Inclusion
- All patients that will be included in the study have cirrhosis as diagnosed by clinical, biochemical, and ultrasound findings, with HRS type 1, the absence of bacterial infections; however, patients with bacterial infections could be included in the study if renal failure persisted after infection resolution by clinical, laboratory indices up to 48 hours.
Exclusion
- Patients will be excluded if there are advanced cardiovascular diseases due to poor prognosis or any extrahepatic disease that could affect the short-term prognosis, the presence of advanced hepatocellular carcinoma or presence of contraindication to norepinephrine as hypotension due to blood volume deficits except emergency measure, mesenteric or peripheral vascular thrombosis unless there is life-saving procedure, profound hypoxia or hypercarbia.
Key Trial Info
Start Date :
August 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 10 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03455322
Start Date
August 15 2018
End Date
July 10 2020
Last Update
February 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHTMRI
Cairo, Egypt